ABCA1 is believed to affect macrophage inflammatory responses, but the mechanism by which ABCA1 may impact cytokine secretion in macrophages has yet to be fully defined. We observed that the induction of ABCA1 expression in three different cell lines, namely BHK, RAW 264.7 macrophages, and primary bone marrow derived macrophages (BMDMs), results in a significant increase in phosphorylated CREB, a known protein kinase A (PKA) substrate. In RAW macrophages, induction of ABCA1 expression by the LXR-agonist T0901317 is correlated with a decrease in LPS-stimulated secretion of proinflammatory cytokines IL-6 and TNF-α. Additionally, the secretion of anti-inflammatory cytokine IL-10 was increased upon ABCA1 induction. A similar trend was observed in BMDMS: ABCA1-expressing BMDMs released less TNF-α and more IL-10 compared to ABCA1-knockout BMDMs. We speculated that the inflammation modulating effects of ABCA1 in macrophages could be a result of PKA activation. Indeed, we found that the LXR-induced ABCA1 phenotype can be mimicked by cAMP in macrophages. 8-bromo-cAMP, a PKA activator, dose-dependently suppressed inflammatory cytokine secretion while promoting IL-10 release in the absence of ABCA1 expression. Finally, we found that the T0901317-induced ABCA1 expression is correlated with higher expression levels of MKP-1, a downstream target of PKA known to suppress inflammatory responses. Together, our results suggest that ABCA1 expression may activate PKA and CREB and that such activation may contribute to the inflammatory modulating effects of ABCA1.

ABCA1 is believed to affect macrophage inflammatory responses, but the mechanism by which ABCA1 may impact cytokine secretion in macrophages has yet to be fully defined. We observed that the induction of ABCA1 expression in three different cell lines, namely BHK, RAW 264.7 macrophages, and primary bone marrow derived macrophages (BMDMs), results in a significant increase in phosphorylated CREB, a known protein kinase A (PKA) substrate. In RAW macrophages, induction of ABCA1 expression by the LXR-agonist T0901317 is correlated with a decrease in LPS-stimulated secretion of proinflammatory cytokines IL-6 and TNF-α. Additionally, the secretion of anti-inflammatory cytokine IL-10 was increased upon ABCA1 induction. A similar trend was observed in BMDMS: ABCA1-expressing BMDMs released less TNF-α and more IL-10 compared to ABCA1-knockout BMDMs. We speculated that the inflammation modulating effects of ABCA1 in macrophages could be a result of PKA activation. Indeed, we found that the LXR-induced ABCA1 phenotype can be mimicked by cAMP in macrophages. 8-bromo-cAMP, a PKA activator, dose-dependently suppressed inflammatory cytokine secretion while promoting IL-10 release in the absence of ABCA1 expression. Finally, we found that the T0901317-induced ABCA1 expression is correlated with higher expression levels of MKP-1, a downstream target of PKA known to suppress inflammatory responses. Together, our results suggest that ABCA1 expression may activate PKA and CREB and that such activation may contribute to the inflammatory modulating effects of ABCA1.

ABCA1 is believed to affect macrophage inflammatory responses, but the mechanism by which ABCA1 may impact cytokine secretion in macrophages has yet to be fully defined. We observed that the induction of ABCA1 expression in three different cell lines, namely BHK, RAW 264.7 macrophages, and primary bone marrow derived macrophages (BMDMs), results in a significant increase in phosphorylated CREB, a known protein kinase A (PKA) substrate. In RAW macrophages, induction of ABCA1 expression by the LXR-agonist T0901317 is correlated with a decrease in LPS-stimulated secretion of proinflammatory cytokines IL-6 and TNF-α. Additionally, the secretion of anti-inflammatory cytokine IL-10 was increased upon ABCA1 induction. A similar trend was observed in BMDMS: ABCA1-expressing BMDMs released less TNF-α and more IL-10 compared to ABCA1-knockout BMDMs. We speculated that the inflammation modulating effects of ABCA1 in macrophages could be a result of PKA activation. Indeed, we found that the LXR-induced ABCA1 phenotype can be mimicked by cAMP in macrophages. 8-bromo-cAMP, a PKA activator, dose-dependently suppressed inflammatory cytokine secretion while promoting IL-10 release in the absence of ABCA1 expression. Finally, we found that the T0901317-induced ABCA1 expression is correlated with higher expression levels of MKP-1, a downstream target of PKA known to suppress inflammatory responses. Together, our results suggest that ABCA1 expression may activate PKA and CREB and that such activation may contribute to the inflammatory modulating effects of ABCA1.

ABCA1 is believed to affect macrophage inflammatory responses, but the mechanism by which ABCA1 may impact cytokine secretion in macrophages has yet to be fully defined. We observed that the induction of ABCA1 expression in three different cell lines, namely BHK, RAW 264.7 macrophages, and primary bone marrow derived macrophages (BMDMs), results in a significant increase in phosphorylated CREB, a known protein kinase A (PKA) substrate. In RAW macrophages, induction of ABCA1 expression by the LXR-agonist T0901317 is correlated with a decrease in LPS-stimulated secretion of proinflammatory cytokines IL-6 and TNF-α. Additionally, the secretion of anti-inflammatory cytokine IL-10 was increased upon ABCA1 induction. A similar trend was observed in BMDMS: ABCA1-expressing BMDMs released less TNF-α and more IL-10 compared to ABCA1-knockout BMDMs. We speculated that the inflammation modulating effects of ABCA1 in macrophages could be a result of PKA activation. Indeed, we found that the LXR-induced ABCA1 phenotype can be mimicked by cAMP in macrophages. 8-bromo-cAMP, a PKA activator, dose-dependently suppressed inflammatory cytokine secretion while promoting IL-10 release in the absence of ABCA1 expression. Finally, we found that the T0901317-induced ABCA1 expression is correlated with higher expression levels of MKP-1, a downstream target of PKA known to suppress inflammatory responses. Together, our results suggest that ABCA1 expression may activate PKA and CREB and that such activation may contribute to the inflammatory modulating effects of ABCA1.

No description available.

La douleur neuropathique est un syndrome secondaire à une maladie ou à une lésion affectant le système nerveux somatosensoriel. Environ 30% des patients souffrant de douleurs neuropathiques présentent des troubles de l’humeur. Les causes biologiques de ces comorbidités ne sont pas clairement établies. Grâce à l’utilisation d’un modèle murin de douleur neuropathique, nous avons cherché à comprendre l’apparition des conséquences émotionnelles de cette douleur. Pour cela, nous avons cherché à identifier des régions cérébrales impliquées dans les différentes composantes et conséquences de la douleur ainsi que les modifications moléculaires y prenant place. Nous avons mis en évidence une ségrégation corticale de la douleur avec l’intégration de la composante sensorielle par le cortex insulaire postérieur d’une part et l’intégration de la composante aversive et des conséquences émotionnelles par le cortex cingulaire antérieur d’autre part. Nous avons ensuite montré l’implication de la protéine MKP-1 dans l’expression des comportements de type anxiodépressif dans notre modèle. / Neuropathic pain is defined as a pain caused by a lesion or disease of the somatosensory nervous system. Around 30% of neuropathic pain patients develop mood disorders. The biologic bases of these comorbidities are not clearly established. Using a murine model of neuropathic pain, we tried to understand the emotional consequences of neuropathic pain. Thus, we identified cerebral regions involved in the different components of pain and molecular modifications taking place in these regions. We showed a cortical separation of the pain experience with on one hand the integration of the sensory component of pain in the posterior insular cortex and on the other hand the integration of the aversive component and the emotional consequences of pain in the anterior cingulate cortex (ACC). Looking at the molecular modifications in the ACC, we showed that MKP-1, a protein able to dephosphorylate the MAPK, is involved in the development of pain-related mood disorders in our model of neuropathic pain.

Phosphorylierung und Dephosphorylierung gehören zu den zentralen Regulationsmechanismen jeder Zelle. Während einer der bekanntesten Signalwege, der Mitogen-aktivierte Protein-Kinase(MAPK)-Signalweg bereits intensiv untersucht wurde, ist über die MAPK-Phosphatasen als wesentliche Inaktivatoren dieser Signalwegfamilie bisher nur wenig bekannt. Die MAPK-Signalwege sind in Tumoren häufig aktiv. Dies ließe sich durch aktivierende Mutationen der Kinasen oder ihrer übergeordneten Rezeptoren erklären. Ein anderer Ansatz geht von der stromalen Entzündungsreaktion aus, die viele solide Tumoren begleitet. Zytokine, die durch die Entzündungszellen gebildet werden, sind physiologische Aktivatoren der MAPK und eine fehlende Gegenregulation durch inaktivierende Phosphatasen würde ebenso zu hoher Aktivität der MAPK führen. In der vorliegenden Arbeit wurde ein solches Entzündungsgeschehen in Ovarialkarzinomzellinien simuliert und die Reaktion der Phosphatasen MKP-1 und MKP-3 auf proinflammatorische Zytokine untersucht. MKP-1 und MKP-3 reagierten mit erheblichen Unterschieden auf die Zugabe proinflammatorischer Zytokine, das Reaktionsmuster reichte von starker Aktivierung (MKP-1 in SKOV-3 und OVCAR-3) bis hin zu verringerter Aktivität der Phosphatasen (MKP-1 in OAW42 und CAOV-3). Zur Ergänzung der Zellkulturstudien wurde die Expression der Phosphatase MKP-1 in primären Ovarialkarzinomen, Zystadenomen sowie gesunden Ovarien immunhistochemisch untersucht. Der Proteinnachweis in insgesamt 101 Gewebeproben ergab eine signifikant geringere Expression der Phosphatase MKP-1 in Karzinomen im Vergleich zu normalem Ovarialepithel oder Zystadenomen. Innerhalb der Gruppe der Karzinome zeigte die MKP-1-Expression dennoch eine hohe Varianz, hierbei waren Malignome mit deutlicher MKP-1-Expression mit einer wesentlich schlechteren Prognose der Erkrankung verbunden. Die Phosphatase war in der multivariaten Analyse des rezidivfreien Überlebens ein unabhängiger Prognoseparameter (RR=4,03; 95%CI=1,72-9,48; p=0,001). Ein kürzeres rezidivfreies Überleben ist häufig mit der frühen Entwicklung von Chemoresistenzen verbunden. Ein möglicher Zusammenhang zwischen der Phosphatase MKP-1 und Chemoresistenz wurde in Zellkulturversuchen unter Verwendung von Cisplatin, einem wesentlichen Bestandteil der Standardchemotherapie bei Ovarialkarzinomen, untersucht. Die Expression der MKP-1 konnte durch Zugabe von Cisplatin deutlich induziert werden. Bemerkenswerterweise zeigten resistente Zellinien dabei eine frühe Reaktion, sensible Zellen reagierten deutlich verzögert. Diese frühe Induktion der MKP-1 könnte die therapeutisch induzierte Apoptose blockieren. Weitere Erkenntnisse über die daran beteiligten Signalwege sowie pharmakologische Inhibitoren der Phosphatasen sind daher vielversprechende Ansätze zur Optimierung der Chemotherapie. / Protein phosphorylation and dephosphorylation is a central regulatory system of cells. The mitogen-activated-protein-kinase(MAPK)-pathway as a typical example is one of the most investigated signalling pathways in cancers. In contrast, much less is known about MAPK-phosphatases, their physiological inactivators. MAPK pathways are frequently up-regulated in cancers. This might be explained by activating mutations of kinases or of up-stream receptors. Another view is based on the inflammatory stroma infiltrate that accompanies most solid carcinomas. Cytokines produced by inflammatory cells are physiological activators of MAPK pathways and missing balance of inactivating phosphatases would also result in up-regulated MAPK pathways. In this study, such an inflammatory situation was simulated in cell culture models and expression patterns of MAPK-phosphatases MKP-1 and MKP-3 were investigated after addition of proinflammatory cytokines. The expression of MKP-1 and MKP-3 after cytokine addition differed widely between the ovarian cancer cell lines investigated, ranging from strong induction in SKOV-3 and OVCAR-3 to down-regulation of phosphatases in OAW42 and CAOV-3. In addition to cell culture experiments, expression of MKP-1 was examined immunohistochemically in primary ovarian cancers, adenomas and normal ovaries (total of 101 samples). There was a lower expression of phosphatase MKP-1 in ovarian cancers compared to surface epithelium of normal ovaries and cystadenomas. However, MKP-1 expression in the group of carcinomas showed a high variation, including also a number of negative cases. Among all investigated cancer samples, those with a higher expression of MKP-1 were associated with poorer prognosis. Multivariate survival analysis revealed this phosphatase as an independant prognostic factor for progression-free survival (RR=4,03; 95%CI=1,72-9,48; p=0,001). Short progression-free survival is usually associated with early development of chemoresistance. Consequently, poor prognosis might result from different efficiencies of initial adjuvant chemotherapeutical treatments. Based on this presumption, the effects of cisplatin, a typically used drug against ovarian cancer, were investigated in cell culture. The phosphatase MKP-1 was highly inducable by cisplatin, remarkably as early reaction in cisplatin-resistant cell lines and with distinct delay in sensitive cells. This early induction of MKP-1 in resistant cells might block drug-induced apoptosis. Further studies about influencing pathways and pharmacological inhibitors of phosphatase MKP-1 might be promising efforts to optimize chemotherapy.

Le TNF-α est une cytokine pro-inflammatoire du système immunitaire qui, lorsque sa production est déréglée, induit de nombreuses pathologies chez l’homme (cachexie, arthrite rhumatoïde, etc.) Outre une régulation transcriptionnelle de cette cytokine, il existe aussi une régulation post-transcriptionnelle permettant un contrôle affiné de sa production. Le laboratoire de Biologie du Gène étudie cette régulation post-transcriptionnelle faisant intervenir une séquence consensus dans l’ARNm appelée séquence AU-riche (ou ARE pour AU-rich element) et les protéines qui y sont impliquées. Généralement, les ARNm porteurs d’ARE codent pour des protéines dont l’expression est transitoire. Ces gènes requièrent un contrôle très précis de leur expression et c’est pourquoi, en plus d’être soumis à de nombreux contrôles transcriptionnels, la traduction et la stabilité de leurs ARNm sont très finement régulées. La réponse immune innée implique de nombreux ARNm de ce type. Jusqu’à présent, la fonction de la protéine TIAR dans la régulation de l’expression du TNF-α n’a pas été complètement élucidée. Outre le TNF-α, la participation à la réponse immune innée de nombreuses protéines encodées par des ARNm porteurs d’ARE pourrait conférer à la protéine TIAR un rôle de régulateur essentiel dans le contrôle de l’inflammation. Nous avons donc générés plusieurs lignées de macrophages RAW 264.7 surexprimant la protéine TIAR entière ou différents mutants de TIAR afin de déterminer, par une analyse globale par puces à ADN, les ARNm cibles de TIAR au cours de la réponse immune. Cette approche nous a permis de démontrer que la protéine TIAR exerce un contrôle sur le métabolisme de l’ARNm du TNF-α et de MKP-1 (MAP kinase phosphatase 1), une phosphatase majeure dans la voie de signalisation de la MAPK p38. Cette voie de signalisation joue un rôle essentiel dans la stabilisation et la traduction de nombreux ARNm porteurs d’ARE encodant des protéines de la réponse inflammatoire. D’autre part, nous avons voulu étudier in vivo la fonction de la protéine TIAR au cours de la réponse immune. Nous avons, dans ce but, généré des souris transgéniques surexprimant l’isoforme courte de la protéine TIAR. Si nous n’avons pas encore pu mesurer les effets d’une surexpression de TIAR sur la réponse inflammatoire chez ces souris, ces individus transgéniques ont révélé qu’une expression anormale de la protéine TIAR induit une létalité importante au cours du développement embryonnaire.

Thesis MSc (Physiological Sciences))--University of Stellenbosch, 2010. / ENGLISH ABSTRACT: Ischaemic heart disease is a leading cause of death worldwide and is also largely contributing to deaths in Africa. Better treatment or even prevention of ischaemia/reperfusion injury in the heart, necessitates a better understanding of the molecular pathways and mechanisms of cell death. Three types of cell death can occur in the diseased myocardium. Type I, better known as apoptotic cell death, is characterised by cell shrinkage and chromatin condensation, type II, known as autophagic cell death, is characterised by intracellular accumulation of double membranes vacuoles and type III, necrotic cell death, is characterised by cellular swelling and loss of membrane integrity. Many signaling pathways are activated during ischaemia/reperfusion injury which include the mitogen activated protein kinases (MAPKs), such as extracellular signal-regulated protein kinase (ERK), c-Jun NH2-terminal protein kinase (JNK) and p38 MAPK. These kinases are dephosphorylated by appropriate phosphatases. MAPK phosphatase-1 (MKP-1), a dual specificity phosphatase, inactivates the MAPKs by dephosphorylating specific Thr/Tyr residues. Upregulation of MKP-1 during ischaemia/reperfusion injury has been shown to be cardioprotective, however no knowledge regarding a role of MKP-1 in autophagy exists. Therefore the aim of this study is to investigate the role of MKP-1 in autophagy, apoptosis and necrosis during simulated ischaemia/reperfusion injury in the heart.METHOD: H9C2 cells (rat cardiomyocytes) were cultured under standard conditions. Upon reaching 75-80% confluency, cells were treated for 30 min during normoxic conditions with dexamethasone, to induce MKP-1 expression, or sanguinarine, to inhibit MKP-1 induction. Thereafter, they were exposed to 3 hrs simulated ischaemia (induced by an ischaemic buffer and 5% CO2/1% O2) in the presence of the above mentioned treatments. Cells were then allowed to reperfuse for 30 min in the presence of dexamethasone or sanguinarine. Samples were analysed after simulated ischaemia and after reperfusion. Cell viability was measured by MTT assay. Propidium iodide and Hoechst staining were used to assess morphological markers of apoptosis and necrosis. LDH release during reperfusion was assessed as indicator of necrotic cell death. LysoTracker®Red was used to visualise the autophagic flux occurring during ischaemia/reperfusion in the cell. Flow cytometry was used to quantify cells stained with acridine orange as indicator for autophagy. Autophagic and apoptotic protein markers as well as MAPK and MKP-1 activity were analysed by Western Blotting. RESULTS: Our results indicate a clear relationship between MKP-1 induction, autophagy and cell survival during simulated ischaemia/reperfusion (SI/R). MKP-1 inhibition during SI/R resulted in decreased autophagy activity accompanied by significant apoptotic and necrotic cell death. Increased MKP-1 induction, on the other hand, during SI/R resulted in increased levels of autophagy activity and subsequent attenuation of apoptotic and necrotic cell death. p38 MAPK phosphorylation was significantly higher while MKP-1 was inhibited and significantly lower while MKP-1 was induced. This strongly indicates that upregulation of MKP-1, known to attenuate ischaemia/reperfusion injury, has an important role in cell survival during ischaemia/reperfusion injury in the heart, through its involvement in the regulation of autophagic activity as a stress response against apoptotic or necrotic cell death. / AFRIKAANSE OPSOMMING: Iskemiese hartsiekte is een van die grootste oorsake van sterftes wêreldwyd en dra ook beduidend by tot sterftes in Afrika. Om iskemiese hartsiektes te behandel of selfs te voorkom, is 'n goeie begrip van die molekulêre paaie wat betrokke is tydens iskemie/herperfusie, noodsaaklik. Drie tipes seldood kom tydens patologiese toestande in die hart voor. Tipe I, ook bekend as apoptotiese seldood, word gekenmerk deur selkrimping en kromatien kondensasie, tipe II, ook bekend as autofagiese seldood word gekenmerk deur intrasellulêre opeenhoping van dubbelmembraan vakuole en tipe III, bekend as nekrotiese seldood, word deur sellulêre swelling en verlies van membraan integriteit gekenmerk. Iskemie/herperfusie lei tot die aktivering van seintransduksiepaaie wat die MAPKs, soos p38, ERK en JNK insluit. Hierdie kinases word deur die gepaste fosfatases gedefosforileer. MKP-1, 'n dubbele spesifieke fosfatase, deaktiveer MAPKs deur hul Thr/Tyr eenhede te defosforileer. Alhoewel daar al voorheen getoon is dat verhoogte MKP-1 ‘n beskermende funksie in die hart tydens iskemie/herperfusie het, is daar nog geen bewyse vir ‘n rol van MKP-1 tydens autofagie nie. Die doel van hierdie studie is dus om die rol van MKP-1 in autofagie, apoptose en nekrose te ondersoek tydens gesimuleerde iskemie/herperfusie in die hart. METODE: H9C2 selle (rot ventrikulêre hartselle) is onder standaard toestande gekweek. Wanneer die selle 75-80% konfluensie bereik het, is dit behandel met dexamethasone of sanguinarine onder standaard toestande vir 30 min. Daarna is selle blootgestel aan 3 ure iskemie, in die teenwoordigheid van dexamethasone of sanguinarine. Selle is dan toegelaat om vir 30 min te herperfuseer, weer in die teenwoordigheid van dexamethasone of sanguinarine. Monsters is na iskemie en herperfusie geneem vir analise. Selvatbaarheid is gekwantifiseer deur ‘n MTT bepaling. Morfologiese merkers van seldood is bepaal met behulp van propidium iodide en Hoechst kleuringsmetodes. Laktaatdehidrogenase (LDH) vrystelling tydens herperfusie is as merker van nekrose gebruik. Autofagie is gevisualiseer deur gebruik te maak van LysoTracker®Red kleuring tydens iskemie en herperfusie. Akridienoranje is gebruik om suur kompartemente te kleur. Vloeisitometrie is as kwantifiseringstegniek vir autofagie gebruik. Western Blotting is gebruik om uitdrukking van merkerproteïene van autofagie en apoptose sowel as MAPK en MKP-1 aktiwiteit tydens iskemie/reperfisie te bepaal. RESULTATE: Ons resultate toon ‘n verband tussen MKP-1 induksie, autofagie en seloorlewing gedurende gesimuleerde iskemie/herperfusie (SI/R) aan. MKP- 1 inhibisie gedurende SI/R het tot ‘n afname in autofagie gelei tesame met ‘n beduidende toename in apoptotiese en nekrotiese seldood. Verhoogde MKP-1 induksie gedurende SI/R, daarteenoor, het autofagiese aktiwiteit verhoog, gepaardgaande met ‘n verlaging in apoptose en nekrose. p38 MAPK fosforilasie was beduidend hoër tydens MKP-1 inhibisie en laer met MKP-1 induksie. Hierdie resultate toon dat MKP-1 ‘n belangrike rol in seloorlewing speel tydens iskemie/herperfusiesskade in die hart, deur sy deelname in die regulering van autofagiese aktiwiteit as ‘n stres reaksie teen apoptotiese en nekrotiese seldood.

Une des complications importantes d’un traitement intensif de chimio/radio-thérapie est l’aplasie de la moelle osseuse qui peut persister longtemps même après une greffe de cellules souches. Le PBI-1402 est un petit lipide qui a été associé à la diminution de l’apoptose des neutrophiles induite par des agents cytotoxiques. Nos travaux ont démontré que la culture in vitro de progéniteurs hématopoiétiques humains en présence de PBI-1402 induit une augmentation significative du nombre de progéniteurs érythroides (PEryth) (p<0,05). En évaluant la sensibilité des PEryth à l’érythropoietine (Epo), nous avons démontré que le PBI-1402 n’a pas d’effet sensibilisateur et que les cellules répondent de façon similaire aux cellules contrôles. De plus, la combinaison de l’Epo et du « stem cell factor » avec le PBI-1402 permet de prolonger et d’augmenter l’activation d’ERK1/2 (p<0,05), un important signal mitogène. Cet effet est associé à une inhibition de l’activation de la phosphatase MKP-1 dans les cellules exposées au PBI-1402. Nous démontrons aussi la capacité du PBI-1402 à amplifier la prolifération des PEryth et sa capacité à réduire la durée et l’intensité de l’anémie dans un modèle in vivo murin. Des souris ayant reçu une dose létale d’irradiation et subi une transplantation syngénique de moelle osseuse, ont été traitées oralement avec le PBI-1402 pendant 14 jours. Ces souris démontrent une réduction significative de l’anémie post-transplantation versus les souris contrôle (p<0,05). De plus, la moelle osseuse des souris traitées au PBI-1402 présente un nombre de BFU-E et CFU-E plus élevé comparativement au contrôle. Ces résultats démontrent donc le potentiel du PBI-1402 à réduire l’anémie post-transplantation et accélérer la reconstitution érythroïde. / One of the most important complications of intensive radiotherapy or chemotherapy is cytopenia, which can persist for significant amount of time even after stem cell transplantation. PBI-1402, a small lipid, was previously shown to be associated with decreased neutrophil apoptosis caused by cytotoxic agents. Our work has shown that day primary human hematopoietic cell in vitro culture in the presence of PBI-1402 resulted in an increased number of erythroid progenitors (p<0,05). Dose-response experiments evaluating sensitivity to erythropoietin (Epo) of cells exposed to PBI-1402 indicated that PBI-1402 did not have a sensitizing effect and that both treated and control cells respond similarly to Epo. In addition, PBI-1402, used in combination with stem cell factor (SCF) and Epo, enhanced and prolonged ERK1/2 phosphorylation (p<0.05), a signalling pathway important for erythroid progenitor cell proliferation. This effect was associated with a decrease of the phosphatase MKP-1 activation in PBI-1402 exposed cells. This translated into and increased proliferation of erythroid progenitors as well as a reduced duration and level of anemia in an in vivo murine transplantation model. Lethally irradiated mice that received syngeneic stem cell transplantation were treated orally with PBI-1402 for 14 days. These mice demonstrated a significant reduction in post-transplantation anemia in a dose dependent manner compared to control (vehicle)(p<0.05). Moreover, PBI-1402-treated mice harboured significantly higher numbers of BFU-E and CFU-E in bone marrow compared to control (p<0.05). These results demonstrate that PBI-1402 treatment significantly reduced transplantation-induced anemia with concomitant acceleration in erythroid recovery.